Last reviewed · How we verify
SLIT Grazax ALK Nordic 75 000 SQ-T
SLIT Grazax ALK Nordic 75 000 SQ-T is a Small molecule drug developed by Lars Olaf Cardell. It is currently in Phase 2 development.
At a glance
| Generic name | SLIT Grazax ALK Nordic 75 000 SQ-T |
|---|---|
| Sponsor | Lars Olaf Cardell |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SLIT Grazax ALK Nordic 75 000 SQ-T CI brief — competitive landscape report
- SLIT Grazax ALK Nordic 75 000 SQ-T updates RSS · CI watch RSS
- Lars Olaf Cardell portfolio CI
Frequently asked questions about SLIT Grazax ALK Nordic 75 000 SQ-T
What is SLIT Grazax ALK Nordic 75 000 SQ-T?
SLIT Grazax ALK Nordic 75 000 SQ-T is a Small molecule drug developed by Lars Olaf Cardell.
Who makes SLIT Grazax ALK Nordic 75 000 SQ-T?
SLIT Grazax ALK Nordic 75 000 SQ-T is developed by Lars Olaf Cardell (see full Lars Olaf Cardell pipeline at /company/lars-olaf-cardell).
What development phase is SLIT Grazax ALK Nordic 75 000 SQ-T in?
SLIT Grazax ALK Nordic 75 000 SQ-T is in Phase 2.